Skip to main content
SpringerLink
Log in

Targeted Modulation of Macrophage Functionality by Nanotheranostics in Inflammatory Liver Disease and Cancer

  • Chapter
  • First Online:
Book cover The Immune Response to Implanted Materials and Devices

  • 1964 Accesses

Abstract

Liver diseases characteristically progress from chronic inflammation to aberrant wound-healing with excessive scarring, termed fibrosis, and eventually to liver cancer. Since hepatic macrophages are critical regulators of these inflammatory processes, it appears promising to target these cells with novel nanomedicine-based therapeutics. Nanomedicine bears a large potential for the design of novel drugs by site-specific delivery and controlled release. Nanotheranostics allow for additional in vivo tracing of the therapeutics. Therapeutic nanoparticles are, in most cases, composed of biodegradable compounds such as phospholipids, which are an essential part of biological membranes. Nanodrugs may interact with soluble parts of the immune system (humoral immunity), specifically with components that help immune cells in pathogen recognition such as antibodies or complement factors. Macrophages are a heterogeneous cell type being composed of pro- or anti-inflammatory subtypes that can either heal or worsen inflammatory diseases as well as combat or support cancer growth. Due to their inherent capability of foreign material uptake, macrophages are relatively easy to target, but may also hinder particles from reaching other target cells. A variety of receptors attractive for targeting was found to be useful in more specific strategies for selectively modulating macrophages to overcome effects on other cell types. In this chapter, current strategies to target macrophages in liver diseases and cancer are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lammers T, Aime S, Hennink WE et al (2011) Theranostic nanomedicine. Acc Chem Res 44(10):1029–1038

    Article  Google Scholar 

  2. Petros RA, DeSimone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9(8):615–627

    Article  Google Scholar 

  3. Bartneck M, Keul HA, Zwadlo-Klarwasser G et al (2010) Phagocytosis independent extracellular nanoparticle clearance by human immune cells. Nano Lett 10(1):59–63

    Article  Google Scholar 

  4. Bartneck M, Warzecha KT, Tacke F (2014) Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surg Nutr 3(6):364–376

    Google Scholar 

  5. Abu Lila AS, Ichihara M, Shimizu T et al (2013) Ex-vivo/in-vitro anti-polyethylene glycol (PEG) immunoglobulin M production from murine splenic B cells stimulated by PEGylated liposome. Biol Pharm Bull 36(11):1842–1848

    Article  Google Scholar 

  6. Pawlotsky JM, Feld JJ, Zeuzem S et al (2015) From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 62(1 Suppl):S87–S99

    Article  Google Scholar 

  7. Bartneck M, Keul HA, Singh S et al (2010) Rapid uptake of gold nanorods by primary human blood phagocytes and immunomodulatory effects of surface chemistry. ACS Nano 4(6):3073–3086

    Article  Google Scholar 

  8. Moghimi SM, Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42(6):463–478

    Article  Google Scholar 

  9. Murray PJ, Allen JE, Biswas SK et al (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41(1):14–20

    Article  Google Scholar 

  10. Martinez FO, Sica A, Mantovani A et al (2008) Macrophage activation and polarization. Front Biosci 13:453–461

    Article  Google Scholar 

  11. Tacke HW, Zimmermann F (2014) Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 60(5):1090–1096

    Article  Google Scholar 

  12. Dal-Secco D, Wang J, Zeng Z et al (2015) A dynamic spectrum of monocytes arising from the in situ reprogramming of CCR2+ monocytes at a site of sterile injury. J Exp Med 212(4):447–456

    Article  Google Scholar 

  13. Bartneck M, Ritz T, Keul HA et al (2012) Peptide-functionalized gold nanorods increase liver injury in hepatitis. ACS Nano 6(10):8767–8777

    Article  Google Scholar 

  14. Bartneck M, Peters FM, Warzecha KT et al (2014) Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages. Nanomedicine 10(6):1209–1220

    Google Scholar 

  15. Sadauskas E, Wallin H, Stoltenberg M et al (2007) Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol 4:10

    Article  Google Scholar 

  16. Csak T, Ganz M, Pespisa J et al (2011) Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54(1):133–144

    Article  Google Scholar 

  17. Karlmark KR, Weiskirchen R, Zimmermann HW et al (2009) Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50(1):261–274

    Article  Google Scholar 

  18. Bataller DA, Brenner R (2005) Liver fibrosis. J Clin Invest 115(2):209–218

    Article  Google Scholar 

  19. Vucur M, Roderburg C, Bettermann K et al (2010) Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma? Oncotarget 1(5):373–378

    Article  Google Scholar 

  20. Ehling J, Tacke F (2016) Role of chemokine pathways in hepatobiliary cancer. Cancer Lett 379(2):173–183

    Article  Google Scholar 

  21. Bartneck M, Fech V, Ehling J et al (2015) Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease. Hepatology 63(4):1310–1324

    Article  Google Scholar 

  22. Wynn TA, Barron L (2010) Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 30(3):245–257

    Article  Google Scholar 

  23. He C, Ryan AJ, Murthy S et al (2013) Accelerated development of pulmonary fibrosis via Cu, Zn-sod-induced alternative activation of macrophages. J Biol Chem 288(28):20745–20757

    Article  Google Scholar 

  24. Meznarich J, Malchodi L, Helterline D et al (2013) Urokinase plasminogen activator induces pro-fibrotic/m2 phenotype in murine cardiac macrophages. PLoS One 8(3), e57837

    Article  Google Scholar 

  25. Tacke C, Trautwein F (2015) Mechanisms of liver fibrosis resolution. J Hepatol 63(4):1038–1039

    Article  Google Scholar 

  26. Mossanen JC, Tacke F (2013) Role of lymphocytes in liver cancer. Oncoimmunology 2(11), e26468

    Article  Google Scholar 

  27. Movahedi K, Laoui D, Gysemans C et al (2010) Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70(14):5728–5739

    Article  Google Scholar 

  28. Bartneck M, Scheyda KM, Warzecha KT et al (2015) Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases. Biomaterials 37:367–382

    Article  Google Scholar 

  29. Kai MP, Brighton HE, Fromen CA et al (2016) Tumor presence induces global immune changes and enhances nanoparticle clearance. ACS Nano 10(1):861–70

    Article  Google Scholar 

  30. Muller RH, Maassen S, Weyhers H et al (1996) Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 4(3):161–170

    Article  Google Scholar 

  31. Bilzer M, Roggel AL, Gerbes F (2006) Role of Kupffer cells in host defense and liver disease. Liver Int 26(10):1175–1186

    Article  Google Scholar 

  32. Pan Y, Neuss S, Leifert A et al (2007) Size-dependent cytotoxicity of gold nanoparticles. Small 3(11):1941–1949

    Article  Google Scholar 

  33. Choi HS, Liu W, Misra P et al (2007) Renal clearance of quantum dots. Nat Biotechnol 25(10):1165–1170

    Article  Google Scholar 

  34. Bartneck M, Keul HA, Wambach M et al (2012) Effects of nanoparticle surface coupled peptides, functional endgroups and charge on intracellular distribution and functionality of human primary reticuloendothelial cells. Nanomedicine 8(8):1282–1292

    Google Scholar 

  35. Beljaars L, Molema G, Weert B et al (1999) Albumin modified with mannose 6-phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 29(5):1486–1493

    Article  Google Scholar 

  36. Blykers A, Schoonooghe S, Xavier C et al (2015) PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments. J Nucl Med 56(8):1265–1271

    Article  Google Scholar 

  37. He C, Yin L, Tang C et al (2013) Multifunctional polymeric nanoparticles for oral delivery of TNF-alpha siRNA to macrophages. Biomaterials 34(11):2843–2854

    Article  Google Scholar 

  38. Melgert BN, Olinga P, Van Der Laan JM et al (2001) Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats. Hepatology 34(4 Pt 1):719–728

    Article  Google Scholar 

  39. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38(1):41–57

    Article  Google Scholar 

  40. Asthana S, Jaiswal AK, Gupta PK et al (2015) Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin B. Eur J Pharm Biopharm 89:62–73

    Article  Google Scholar 

  41. Liu JY, Chiang T, Liu CH et al (2015) Delivery of siRNA using CXCR4-targeted nanoparticles modulates tumor microenvironment and achieves a potent antitumor response in liver cancer. Mol Ther 23(11):1772–1782

    Article  Google Scholar 

  42. Kummerer K, Menz J, Schubert T et al (2011) Biodegradability of organic nanoparticles in the aqueous environment. Chemosphere 82(10):1387–1392

    Article  Google Scholar 

  43. Schulte W, Bernhagen R, Bucala J (2013) Cytokines in sepsis: potent immunoregulators and potential therapeutic targets—an updated view. Mediators Inflamm 2013:165974

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine III, RWTH University Hospital Aachen, Aachen, Germany

    Matthias Bartneck & Frank Tacke

Authors
  1. Matthias Bartneck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Tacke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank Tacke .

Editor information

Editors and Affiliations

  1. Department of Life and Environmental Sciences, Marche Polytechnic University, Ancona, Italy

    Bruna Corradetti

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Bartneck, M., Tacke, F. (2017). Targeted Modulation of Macrophage Functionality by Nanotheranostics in Inflammatory Liver Disease and Cancer. In: Corradetti, B. (eds) The Immune Response to Implanted Materials and Devices. Springer, Cham. https://doi.org/10.1007/978-3-319-45433-7_11

Download citation

Publish with us

Policies and ethics

Search

Navigation